CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
复制标题
DOI：
10.1309/w01y0b808emeh12l
复制
发表时间：
2008-04-01
影响因子：
3.5
通讯作者：
Montine, Thomas J.
中科院分区：
文献类型：
--
作者：
Zhang, Jing;Sokal, Izabela;Montine, Thomas J.
阿尔茨海默病(AD)和帕金森病(PD)的治疗迫切需要发现和验证生物标志物。脑脊液tau增加和淀粉样蛋白(A)β减少(42)已被证实为AD的生物标志物。相比之下，目前尚无有效的脑脊液生物标志物用于诊断帕金森病。我们从95名对照受试者、48名可能的AD患者和40名可能的PD患者的脑脊液中验证了我们的蛋白质组学发现的多分析物图谱(MAP)。对于90名对照受试者(95%)、36名可能患有AD的患者(75%)和38名可能患有PD的患者(95%)，最优的8人MAP与专家诊断一致。该图谱由以下组成(按贡献从大到小的顺序排列)：tau、脑源性神经营养因子、白细胞介素8、Aβ(42)、β(2)-微球蛋白、维生素D结合蛋白、载脂蛋白(Apo)AII和apoE。首次对蛋白质组发现的图谱进行大规模验证，提出了一组8种脑脊液蛋白质，它们在识别PD方面非常有效，在识别AD方面中等有效。
The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta(42) have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, A beta(42), beta(2)-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.